ARTICLE | Company News
Zymeworks, GlaxoSmithKline deal
May 2, 2016 7:00 AM UTC
Zymeworks granted GlaxoSmithKline an option to license molecules developed using the biotech’s Azymetric bispecific antibody discovery platform. Zymeworks will receive up to $36 million in upfront and...